With Sensus’ superficial radiation therapy (SRT), we may be entering uncharted waters where keloid recurrence after surgery and SRT leads to no, or a very low, incidence of keloid recurrence. With this, we will change the paradigm in the treatment of keloids.
The Sensus SRT-100 is a superficial radiation device that has FDA clearance—the first radiation therapy device to achieve this—and shows very high efficacy and safety in treating not only the difficult-to-treat keloids but also non-melanoma skin cancers. My practice is pleased to offer this to our patients, and the response, thus far, has been overwhelmingly positive.
Our office, Gold Skin Care Center in Nashville, is a go-to center for patients who suffer from keloids, as we have been performing clinical research on these kinds of lesions for more than 25 years. We have worked with many different companies and products to look at how we treat keloids more effectively and how we can reduce the chance of treated keloids from recurring. This, obviously, has been a frustrating endeavor, and despite our initial research, the vast majority of keloids that we’ve treated thus far have the propensity of recurrence.
I’ve had the privilege of authoring two scientific publications on the treatment of keloids—the International Guidelines on the Treatment of Hypertrophic Scars and Keloids—in 2002 and 2014. In both of these publications, while radiation therapy was reviewed, superficial radiation therapy was not, and this is the kind of radiation that we see with the SRT-100. This technology marks a huge step toward transforming the lives of thousands of patients who have keloids, as well as those who suffer with symptomatic keloids—pain, itching and the like. Using the SRT-100 has been an incredible opportunity for these patients to have their keloids surgically excised and then treated over the course of the two to three days with superficial radiation therapy.
Michael H. Gold, MD | Gold Skin Care Center | Nashville, TN
Source: Modern Aesthetics
